Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Novartis fell 12.7% pre-market to $139.56 after its Phase III Lp(a) HORIZON trial of pelacarsen failed to meet its primary endpoint, triggering a broader selloff in related biotech names. Dyne Therapeutics dropped 35.5%, Sarepta fell 15.6%, and Ionis declined 11.5% in sympathy given its licensing and collaboration agreement with Novartis for pelacarsen. U.S. equity futures were also weaker, with Dow futures down more than 400 points.

Analysis

The failed cardiovascular-outcomes signal should reset the market’s willingness to capitalize Lp(a) lowering as a standalone franchise. IONS has the most direct economic exposure through milestone/royalty optionality, while AMGN, SLN and NAMS face a higher evidentiary bar for their respective programs; the relevant rerating is not just probability of approval, but lower peak-sales assumptions and delayed payer adoption. Over the next 1-3 months, investors will scrutinize whether event curves were neutral despite substantial Lp(a) reduction, which would imply the biology requires earlier intervention, deeper suppression, or patient selection rather than simply more drug exposure.

NVS’s pre-market move may be disproportionate if the asset was not a material contributor to consensus medium-term earnings or if the trial contains a salvageable subgroup. A diversified large-cap pharmaceutical business should be valued on the change in risk-adjusted pipeline NPV, not an extrapolation of the single-asset percentage move; detailed efficacy, safety, baseline Lp(a), and achieved reduction data are required before treating this as a durable fundamental impairment. Conversely, a clearly neutral result across high-Lp(a) patients would be a structural negative for the entire RNA/antisense cardiometabolic platform and could pressure sector multiples for 6-18 months.

The selloff in DYN and SRPT lacks an apparent fundamental transmission mechanism and is more likely a risk-off liquidity/beta event than a change in their development probabilities. Avoid converting broad biotech weakness into a thesis unless subsequent data, financing activity, or regulatory developments independently alter their cash runways. The key contrarian point is that this may be a trial-design failure rather than target invalidation; any evidence of benefit in the highest-risk or highest-Lp(a) strata would sharply reverse indiscriminate peer shorts.

Key Decisions for Investors

• Do not add to IONS on the initial decline; maintain a 1-3 month underweight versus XBI until full subgroup and event-curve data establish whether its Lp(a) economics retain value. Cover if results show a clinically credible high-risk subgroup benefit or management preserves material milestone/royalty guidance.
• Use a staged long NVS only after the conference call/data release if management quantifies a limited earnings/FCF effect and the stock remains down materially more than the estimated risk-adjusted asset NPV. Target a 3-6 month normalization trade; invalidate on broader pipeline guidance cuts or evidence that the program supported a meaningful portion of long-range sales expectations.
• Avoid fresh longs in AMGN, SLN, and NAMS until trial details distinguish target failure from molecule-specific execution. Establish alerts around each company’s next Lp(a) efficacy/outcomes update; a class-wide short is premature without confirmation that deeper suppression and patient enrichment fail to improve outcomes.
• Treat DYN and SRPT weakness as technical rather than fundamental: no directional trade from this signal alone. Reassess only if the drawdowns produce financing-risk levels—cash runway, dilution terms, and regulatory timing are the relevant catalysts, not cardiovascular-outcomes readthrough.